Table 2: Cohort studies demonstrating no association between oxidized low-density lipoprotein measurement and cardiovascular events.

Oxidative oxLDL testPopulation under studyCV endpointsNumber of eventsFollowup FindingsReference

OxLDL Abs 4E063033 elderlyCV events418 IHD, 120 MI3 yearsOxLDL did not predict CV events at MV analysisHolvoet et al. [95]

AutoAbs MDA-oxLDL 2619 subjectsIHD (angina, ACS, and IHD death); CV events (IHD + TIA/stroke)151 IHD, 234 CV events8 yearsAutoAbs did not predict CV eventsWilson et al. [99]

OxLDL Abs 4E06, AutoAbs MDA-/Cu-oxLDL919 subjectsCarotid atherosclerosis progressionna5 yearsAutoAbs and oxLDL did not predict CV eventsMayr et al. [100]

AutoAbs Cu-oxLDL92 NIDDM, 80 ctrCV events34 CV events, 15 CV deaths 10 yearsAutoAbs did not predict CV eventsUusitupa et al. [96]

OxLDL Abs 4E0669 ESRD on hemodialysis, 33 ctrCV events18 CV events43 monthsOxLDL did not predict CV eventsLee et al. [101]

AutoAbs Cu-oxLDL415 IHDCV events35 CV deaths/MI, 33 PTCA/CABG5 yearsAutoAbs did not predict CV eventsErkkil et al. [97]

OxLDL Abs 4E06687 PTCA ptsRestenosis, CV events135 restenosis, 181 CV events1 yearOxLDL did not predict CV eventsBraun et al. [98]

Abs: antibodies; AutoAbs: autoantibodies; CABG: coronary artery by-pass surgery; CHF: congestive heart failure; Crt: controls; CV: cardiovascular; ESRD: end-stage renal disease; IHD: ischemic heart disease; IMT: intima-media thickness; MI: myocardial infarction; NIDDM: noninsulin dependent diabetes mellitus; oxLDL: oxidized low-density lipoproteins; PTCA: percutaneous transluminal coronary angioplasty; pts: patients.